<p>Pulse Biosciences, Inc.（納斯達克股票代碼：PLSE - 獲取免費報告）在六月份看到了空頭頭寸大幅下降。截至 6 月 15 日，空頭頭寸總計 2,430,000 股，較 5 月 31 日的 2,840,000 股減少了 14.4%。根據平均每日交易量為 220,500 股，目前的空頭頭寸比率為 11.0 天。目前，該公司的 14.9% 股份被空頭持有。</p>
<p>獲取 <strong>Pulse Biosciences</strong> 警報：</p>
<h2>Pulse Biosciences 股票表現</h2>
<p>納斯達克 PLSE 股票週五開盤價為$11.19。Pulse Biosciences 過去 12 個月的最低價為$3.78，最高價為$14.96。該公司的 50 天簡單移動平均價為$10.06，200 天簡單移動平均價為$9.55。</p>
<p>Pulse Biosciences（納斯達克股票代碼：PLSE - 獲取免費報告）最近公佈了其截至 5 月 7 日星期二的季度財報數據。該公司報告該季度每股虧損為（$0.17）。</p>
<h2>華爾街分析師觀點</h2>
<p>StockNews.com 在一份研究報告中將 Pulse Biosciences 股票評級升級為 “賣出”。</p>
<p><strong>閲讀我們關於 Pulse Biosciences 的最新報告</strong></p>
<h2>內部人員的買賣行為</h2>
<p>據相關消息，首席執行官 Burke Thomas Barrett 於 5 月 20 日星期一購買了該公司 10,000 股股票。股票的平均購入成本為每股$8.56，總交易額為$85,600.00。購買後，首席執行官現在直接持有該公司 10,000 股股票，價值$85,600。該購買行為已在提交給證券交易委員會的文件中披露，可通過此超鏈接訪問。公司股份的 71.50% 歸內部人員所有。</p>
<h2>對 Pulse Biosciences 的對沖基金觀點</h2>
<p>一些大型投資者最近調整了他們在 PLSE 的持倉。BNP Paribas Financial Markets 在第一季度將其在 Pulse Biosciences 的持股比例提高了 63.6%。BNP Paribas Financial Markets 現在擁有 7,597 股該公司股票，價值$66,000，比上期增加了 2,952 股。Price T Rowe Associates Inc. MD 在第一季度新買入了 Pulse Biosciences 的股票，價值$88,000。Cetera Advisors LLC 在第一季度新買入了 Pulse Biosciences 的股票，價值$109,000。PNC Financial Services Group Inc.在第四季度新買入了 Pulse Biosciences 的股票，價值$242,000。最後，Inspire Investing LLC 在第一季度將其在 Pulse Biosciences 的持股比例提高了 32.1%。Inspire Investing LLC 現在擁有 41,358 股該公司股票，價值$360,000，比上期增加了 10,039 股。目前，76.95% 的股份由機構投資者和對沖基金持有。</p>
<h2>關於 Pulse Biosciences（獲取免費報告）</h2>
<p>Pulse Biosciences, Inc 是一家新型生物電醫學公司。該公司提供 CellFX 系統，這是一個可調節、軟件啓用和基於控制枱的平台，通過其 Nano-Pulse 刺激技術向非熱清除靶向細胞傳遞納秒持續時間的電能脈衝，同時保護相鄰的非細胞組織，以治療各種疾病。</p>
<h2>推薦故事</h2>
<ul>
<li>我們喜歡的五隻股票比 Pulse Biosciences 更好</li>
<li>股票回購是什麼？投資者的全面指南</li>
<li>Upwork 股票展望：儘管面臨 Gen-AI 挑戰，數字仍堅實</li>
<li>股市板塊：它們是什麼，有多少個？</li>
<li>瓦爾格林斯股票暴跌背後的原因：投資者下一步該怎麼做</li>
<li>什麼是華爾街賭注，他們瞄準哪些股票？</li>
<li>MarketBeat 周評-6/24 - 6/28</li>
</ul>
<p><em>此即時新聞警報由敍事科學技術和 MarketBeat 的財務數據生成，以向讀者提供最快速和最準確的報道。本故事在發佈前經 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ AI 真正的下一步發展方向（來自 InvestorPlace）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTA2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTA2"/></p>
<h2>您現在是否應該投資$1,000 購買 Pulse Biosciences 股票？</h2>
<p>在考慮 Pulse Biosciences 之前，您可能想聽聽這個。</p>
<p>MarketBeat 追蹤華爾街頂級和表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已確定了五隻頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票...而 Pulse Biosciences 不在名單上。</p>
<p>儘管 Pulse Biosciences 目前在分析師中有 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

PLSE

<p>Pulse Biosciences（納斯達克股票代碼：PLSE）在六月份經歷了空頭頭寸的顯著下降，與五月相比下降了 14.4%。目前，該公司的股份中有 14.9% 被空頭賣空。根據平均每日交易量，按照股票的交易天數計算，空頭頭寸的天數為 11.0 天。過去一年，該公司的股價表現在 3.78 美元至 14.96 美元之間波動。首席執行官 Burke Thomas Barrett 最近購買了 10,000 股該公司的股票。機構投資者和對沖基金持有該股約 76.95%</p>

<p>Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report) saw a large drop in short interest in June. As of June 15th, there was short interest totalling 2,430,000 shares, a drop of 14.4% from the May 31st total of 2,840,000 shares. Based on an average daily volume of 220,500 shares, the short-interest ratio is currently 11.0 days. Currently, 14.9% of the shares of the company are sold short.</p>
<div class="lb-trans"><p>Pulse Biosciences, Inc.（納斯達克股票代碼：PLSE - 獲取免費報告）在六月份看到了空頭頭寸大幅下降。截至 6 月 15 日，空頭頭寸總計 2,430,000 股，較 5 月 31 日的 2,840,000 股減少了 14.4%。根據平均每日交易量為 220,500 股，目前的空頭頭寸比率為 11.0 天。目前，該公司的 14.9% 股份被空頭持有。</p>
</div><p>Get <strong>Pulse Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Pulse Biosciences</strong> 警報：</p>
</div><h2>Pulse Biosciences Stock Performance</h2>
<div class="lb-trans"><h2>Pulse Biosciences 股票表現</h2>
</div><p>Shares of NASDAQ PLSE opened at $11.19 on Friday. Pulse Biosciences has a 12 month low of $3.78 and a 12 month high of $14.96. The company has a 50 day simple moving average of $10.06 and a two-hundred day simple moving average of $9.55.</p>
<div class="lb-trans"><p>納斯達克 PLSE 股票週五開盤價為$11.19。Pulse Biosciences 過去 12 個月的最低價為$3.78，最高價為$14.96。該公司的 50 天簡單移動平均價為$10.06，200 天簡單移動平均價為$9.55。</p>
</div><p>Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.17) EPS for the quarter.</p>
<div class="lb-trans"><p>Pulse Biosciences（納斯達克股票代碼：PLSE - 獲取免費報告）最近公佈了其截至 5 月 7 日星期二的季度財報數據。該公司報告該季度每股虧損為（$0.17）。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>Separately, StockNews.com upgraded shares of Pulse Biosciences to a &#34;sell&#34; rating in a research note on Thursday.</p>
<div class="lb-trans"><p>StockNews.com 在一份研究報告中將 Pulse Biosciences 股票評級升級為 “賣出”。</p>
</div><p><strong>Read Our Latest Report on Pulse Biosciences</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Pulse Biosciences 的最新報告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人員的買賣行為</h2>
</div><p>In related news, CEO Burke Thomas Barrett bought 10,000 shares of the stock in a transaction that occurred on Monday, May 20th. The stock was bought at an average cost of $8.56 per share, for a total transaction of $85,600.00. Following the purchase, the chief executive officer now directly owns 10,000 shares of the company's stock, valued at $85,600. The purchase was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. 71.50% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>據相關消息，首席執行官 Burke Thomas Barrett 於 5 月 20 日星期一購買了該公司 10,000 股股票。股票的平均購入成本為每股$8.56，總交易額為$85,600.00。購買後，首席執行官現在直接持有該公司 10,000 股股票，價值$85,600。該購買行為已在提交給證券交易委員會的文件中披露，可通過此超鏈接訪問。公司股份的 71.50% 歸內部人員所有。</p>
</div><h2>Hedge Funds Weigh In On Pulse Biosciences</h2>
<div class="lb-trans"><h2>對 Pulse Biosciences 的對沖基金觀點</h2>
</div><p>Several large investors have recently made changes to their positions in PLSE. BNP Paribas Financial Markets lifted its stake in shares of Pulse Biosciences by 63.6% in the 1st quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company's stock valued at $66,000 after purchasing an additional 2,952 shares during the period. Price T Rowe Associates Inc. MD acquired a new position in shares of Pulse Biosciences in the 1st quarter valued at $88,000. Cetera Advisors LLC acquired a new position in shares of Pulse Biosciences in the 1st quarter valued at $109,000. PNC Financial Services Group Inc. acquired a new position in shares of Pulse Biosciences in the 4th quarter valued at $242,000. Finally, Inspire Investing LLC lifted its stake in shares of Pulse Biosciences by 32.1% in the 1st quarter. Inspire Investing LLC now owns 41,358 shares of the company's stock valued at $360,000 after purchasing an additional 10,039 shares during the period. 76.95% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些大型投資者最近調整了他們在 PLSE 的持倉。BNP Paribas Financial Markets 在第一季度將其在 Pulse Biosciences 的持股比例提高了 63.6%。BNP Paribas Financial Markets 現在擁有 7,597 股該公司股票，價值$66,000，比上期增加了 2,952 股。Price T Rowe Associates Inc. MD 在第一季度新買入了 Pulse Biosciences 的股票，價值$88,000。Cetera Advisors LLC 在第一季度新買入了 Pulse Biosciences 的股票，價值$109,000。PNC Financial Services Group Inc.在第四季度新買入了 Pulse Biosciences 的股票，價值$242,000。最後，Inspire Investing LLC 在第一季度將其在 Pulse Biosciences 的持股比例提高了 32.1%。Inspire Investing LLC 現在擁有 41,358 股該公司股票，價值$360,000，比上期增加了 10,039 股。目前，76.95% 的股份由機構投資者和對沖基金持有。</p>
</div><h2>About Pulse Biosciences (Get Free Report)</h2>
<div class="lb-trans"><h2>關於 Pulse Biosciences（獲取免費報告）</h2>
</div><p>Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.</p>
<div class="lb-trans"><p>Pulse Biosciences, Inc 是一家新型生物電醫學公司。該公司提供 CellFX 系統，這是一個可調節、軟件啓用和基於控制枱的平台，通過其 Nano-Pulse 刺激技術向非熱清除靶向細胞傳遞納秒持續時間的電能脈衝，同時保護相鄰的非細胞組織，以治療各種疾病。</p>
</div><h2>Recommended Stories</h2>
<ul>
<li>Five stocks we like better than Pulse Biosciences</li>
<li>What is a buyback in stocks? A comprehensive guide for investors</li>
<li>Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges</li>
<li>Stock Market Sectors: What Are They and How Many Are There?</li>
<li>What's Behind Walgreens Stock Plunge: What Investors Can Do Next</li>
<li>What Is WallStreetBets and What Stocks Are They Targeting?</li>
<li>MarketBeat Week in Review – 6/24 - 6/28</li>
</ul>
<div class="lb-trans"><h2>推薦故事</h2>
<ul>
<li>我們喜歡的五隻股票比 Pulse Biosciences 更好</li>
<li>股票回購是什麼？投資者的全面指南</li>
<li>Upwork 股票展望：儘管面臨 Gen-AI 挑戰，數字仍堅實</li>
<li>股市板塊：它們是什麼，有多少個？</li>
<li>瓦爾格林斯股票暴跌背後的原因：投資者下一步該怎麼做</li>
<li>什麼是華爾街賭注，他們瞄準哪些股票？</li>
<li>MarketBeat 周評-6/24 - 6/28</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍事科學技術和 MarketBeat 的財務數據生成，以向讀者提供最快速和最準確的報道。本故事在發佈前經 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ Where AI is REALLY Going Next (From InvestorPlace)(Ad)</p>
<div class="lb-trans"><p>→ AI 真正的下一步發展方向（來自 InvestorPlace）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTA2" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8506&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Pulse Biosciences right now?</h2>
<div class="lb-trans"><h2>您現在是否應該投資$1,000 購買 Pulse Biosciences 股票？</h2>
</div><p>Before you consider Pulse Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Pulse Biosciences 之前，您可能想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街頂級和表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已確定了五隻頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票...而 Pulse Biosciences 不在名單上。</p>
</div><p>While Pulse Biosciences currently has a &#34;hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 Pulse Biosciences 目前在分析師中有 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Pulse Biosciences, Inc. (NASDAQ:PLSE) 空頭頭寸最新動態